Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 7/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324799 | 0.78 | GPR119 (0.49) | MMP13GPR119DPP4USP30 | |
| SCHEMBL2675436 | 0.72 | GPR119 (0.45) | MMP13GPR119 | |
| SCHEMBL4114220 | 0.71 | GPR119 (0.53) | GPR119PDE4D | |
| SCHEMBL31663264 | 0.70 | PTPN2 (0.49) | GPR119FAAH | |
| SCHEMBL23672116 | 0.69 | GPR119 (0.42) | MMP13GPR119DPP4FAAH | |
| SCHEMBL586400 | 0.67 | SSTR4 (0.40) | GPR119USP30PDE4D | |
| SCHEMBL19286080 | 0.67 | GPR119 (0.54) | GPR119DPP4PDE4D | |
| SCHEMBL1295933 | 0.67 | GPR119 (0.48) | MMP13GPR119DPP4 | |
| SCHEMBL7871971 | 0.66 | GPR119 (0.57) | GPR119DPP4 | |
| SCHEMBL7871972 | 0.66 | GPR119 (0.57) | GPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | MMP13 3624/4885GPR119 1/4885DPP4 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.